Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is poised for future growth with their unique benefits platform and strong partnerships, while also prioritizing clinical outcomes and member support. Their investment in technology and diverse customer base signals confidence in continued success in the growing fertility benefits market. Strong relationships with clients and a focus on service, combined with a positive financial outlook, make Progyny a promising investment opportunity for the future.

Bears say

Progyny is a highly competitive company in the benefits management industry, with strong market share gains exceeding all privately funded fertility competitors. However, the company has experienced lower client renewal rates due to a temporary distortion in revenue-per-cycle comparisons and a decline in membership. Additionally, while there are several secular tailwinds supporting adoption of fertility benefits, Progyny may not be able to sustain its high level of profitability and cash conversion over the long term.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.